Suppr超能文献

基于 REACH 随机试验的乳腺癌和卵巢癌幸存者的人群样本中的遗传检测:咨询模式的成本障碍和调节因素。

Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.

机构信息

Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.

University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico.

出版信息

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.

Abstract

This study evaluates predictors of 2 testing among breast and ovarian cancer survivors who received genetic counseling as part of a randomized trial and evaluates moderators of counseling mode on testing uptake. Predictors of testing within one year postcounseling were evaluated using multivariable logistic regression in a population-based sample of breast and ovarian cancer survivors at increased hereditary risk randomly assigned to in-person counseling (IPC; = 379) versus telephone counseling (TC; = 402). Variables that moderated the association between counseling mode and testing were identified by subgroup analysis. Testing uptake was associated with higher perceived comparative mutation risk [OR = 1.32; 95% confidence interval (CI), 1.11-1.57] in the adjusted analysis. Those without cost barriers had higher testing uptake (OR = 18.73; 95% CI, 7.09-49.46). Psychologic distress and perceived comparative mutation risk moderated the effect of counseling and testing. Uptake between IPC versus TC did not differ at low levels of distress and risk, but differed at high distress (26.3% TC vs. 44.3% IPC) and high perceived comparative risk (33.9% TC vs. 50.5% IPC). Cost concerns are a strong determinant of testing. Differences in testing uptake by counseling mode may depend on precounseling distress and risk perceptions. Cost concerns may contribute to low testing in population-based samples of at-risk cancer survivors. Precounseling psychosocial characteristics should be considered when offering in-person versus telephone counseling. .

摘要

本研究评估了接受遗传咨询的乳腺癌和卵巢癌幸存者在一年内进行 2 次检测的预测因素,该遗传咨询是一项随机试验的一部分,并评估了咨询模式对检测率的调节作用。在基于人群的、有遗传风险的乳腺癌和卵巢癌幸存者中,评估了咨询后一年内检测的预测因素,这些幸存者被随机分配接受面对面咨询(IPC;n=379)或电话咨询(TC;n=402)。通过亚组分析确定了调节咨询模式与检测之间关联的变量。调整分析显示,较高的感知相对突变风险[比值比(OR)=1.32;95%置信区间(CI),1.11-1.57]与检测率增加相关。无费用障碍的患者检测率更高(OR=18.73;95%CI,7.09-49.46)。心理困扰和感知相对突变风险调节了咨询和检测的效果。在低压力和低风险水平时,IPC 与 TC 之间的检测率没有差异,但在高压力(26.3% TC 比 44.3% IPC)和高感知相对风险(33.9% TC 比 50.5% IPC)时存在差异。费用问题是检测的一个重要决定因素。咨询模式对检测率的影响差异可能取决于咨询前的心理困扰和风险认知。费用问题可能导致高危癌症幸存者的基础人群样本检测率较低。在提供面对面咨询与电话咨询时,应考虑咨询前的心理社会特征。

相似文献

1
Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.
2
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
J Clin Oncol. 2014 Mar 1;32(7):618-26. doi: 10.1200/JCO.2013.51.3226. Epub 2014 Jan 21.
4
Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.
J Natl Cancer Inst. 2014 Nov 5;106(12). doi: 10.1093/jnci/dju328. Print 2014 Dec.
5
Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Eur J Hum Genet. 2019 Aug;27(8):1186-1196. doi: 10.1038/s41431-019-0390-9. Epub 2019 Apr 8.
6
BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
Breast Cancer Res Treat. 2018 Feb;168(1):117-126. doi: 10.1007/s10549-017-4584-y. Epub 2017 Nov 21.
10

引用本文的文献

2
Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control.
J Clin Transl Sci. 2024 Oct 16;8(1):e166. doi: 10.1017/cts.2024.554. eCollection 2024.
3
The Diagnostic Landscape of Adult Neurogenetic Disorders.
Biology (Basel). 2023 Nov 22;12(12):1459. doi: 10.3390/biology12121459.
5
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.
Ther Adv Med Oncol. 2023 Sep 15;15:17588359231189127. doi: 10.1177/17588359231189127. eCollection 2023.
6
The growing needs of genetic counselling-Feasibility in utilization of tele-genetic counselling in Asia and Hong Kong.
Front Genet. 2023 Aug 3;14:1239817. doi: 10.3389/fgene.2023.1239817. eCollection 2023.
9
Public Interest in Population Genetic Screening for Cancer Risk.
Front Genet. 2022 Jul 22;13:886640. doi: 10.3389/fgene.2022.886640. eCollection 2022.
10
The Role of Safety-Net Hospitals in Reducing Disparities in Breast Cancer Care.
Ann Surg Oncol. 2022 Mar 31. doi: 10.1245/s10434-022-11576-3.

本文引用的文献

1
Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
J Natl Compr Canc Netw. 2017 Feb;15(2):219-228. doi: 10.6004/jnccn.2017.0022. Epub 2017 Feb 10.
3
Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
JAMA. 2017 Feb 7;317(5):531-534. doi: 10.1001/jama.2016.16918.
4
Health and Health Care Use Among Individuals at Risk to Lose Health Insurance With Repeal of the Affordable Care Act.
JAMA Intern Med. 2017 Apr 1;177(4):590-593. doi: 10.1001/jamainternmed.2016.9541.
5
Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing.
Expert Rev Mol Diagn. 2017 Jan;17(1):57-70. doi: 10.1080/14737159.2017.1267567. Epub 2016 Dec 13.
7
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
J Natl Compr Canc Netw. 2016 Feb;14(2):153-62. doi: 10.6004/jnccn.2016.0018.
9
Availability and payer coverage of BRCA1/2 tests and gene panels.
Nat Biotechnol. 2015 Sep;33(9):900-2. doi: 10.1038/nbt.3322.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验